{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:02:03Z","timestamp":1787022123960,"version":"build-2736575974"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gr\u00fcnenthal GmbH"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to treat pain and rheumatic conditions. To facilitate patient management, we determined the predictive value of gastrointestinal (GI) symptoms and risk factors for the development of NSAID-associated GI injuries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Post-hoc analysis of pooled data from naproxen treatment arms of two identical, randomized, double-blind, controlled phase 3 trials in arthritis patients at risk of GI adverse events. Endoscopic incidence of GI ulcers at baseline, and 1, 3, and 6 months was employed as a surrogate parameter for GI injury. For GI symptom analysis, Severity of Dyspepsia Assessment questionnaire was used. For GI risk factor analysis, the high risk factors: previous GI injury, concomitant selective serotonin reuptake inhibitors or corticosteroids, ulcer history, concomitant low-dose aspirin, and age &gt;65 years were employed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data of 426 naproxen patients were analyzed. Distribution of GI symptoms between patients with and without ulcer was similar; about one third of patients developing an ulcer reported no GI pain symptoms. GI symptoms experienced under naproxen treatment were thus not indicative of GI injury. The proportion of patients developing an ulcer increased with the number of risk factors present, however, about a quarter of patients without any of the analyzed risk factors still developed an ulcer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GI symptoms and the number of risk factors are not reliable predictors of NSAID-induced GI injury to decide which patients need gastroprotection and will lead to a large group of patients with GI injuries. A preventive rather than reactive approach should be taken.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0284358","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T13:30:11Z","timestamp":1681392611000},"page":"e0284358","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Predictive value of gastrointestinal symptoms and patient risk factors for NSAID-associated gastrointestinal ulcers defined by endoscopy? Insights from a pooled analysis of two naproxen clinical trials"],"prefix":"10.1371","volume":"18","author":[{"given":"Mart A. F. J.","family":"van de Laar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Sch\u00f6fl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlou","family":"Prevoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3885-9983","authenticated-orcid":true,"given":"Jan","family":"Jastorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"issue":"6","key":"pone.0284358.ref001","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00296-011-2263-6","article-title":"A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity","volume":"32","author":"PG Conaghan","year":"2012","journal-title":"Rheumatol Int"},{"issue":"10","key":"pone.0284358.ref002","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/17512433.2018.1516143","article-title":"NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs","volume":"11","author":"G Garc\u00eda-Rayado","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"Suppl 3","key":"pone.0284358.ref003","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar4175","article-title":"Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage","volume":"15","author":"C Sostres","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"645","key":"pone.0284358.ref004","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3399\/bjgp16X684433","article-title":"The dangers of NSAIDs: look both ways","volume":"66","author":"A Davis","year":"2016","journal-title":"Br J Gen Pract"},{"key":"pone.0284358.ref005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gtc.2010.08.010","article-title":"Nonsteroidal anti-inflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention","volume":"39","author":"C Scarpignato","year":"2010","journal-title":"Gastroenterol Clin North Am"},{"key":"pone.0284358.ref006","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-230X-9-41","article-title":"Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use","volume":"9","author":"S Straube","year":"2009","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"pone.0284358.ref007","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000323958","article-title":"Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality","volume":"84","author":"JY Lau","year":"2011","journal-title":"Digestion"},{"issue":"6","key":"pone.0284358.ref008","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/dtb.2019.000072","article-title":"Reducing the risk of NSAID related gastrointestinal problems: an update","volume":"58","author":"M. Bradley","year":"2020","journal-title":"Drug Ther Bull"},{"issue":"9894","key":"pone.0284358.ref009","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"N Bhala","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"pone.0284358.ref010","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1053\/j.gastro.2014.06.007","article-title":"Risk of upper gastrointestinal bleeding from different drug combinations","volume":"147","author":"GM Masclee","year":"2014","journal-title":"Gastroenterology"},{"key":"pone.0284358.ref011","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/gut.2005.080754","article-title":"Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations","volume":"55","author":"A Lanas","year":"2006","journal-title":"Gut"},{"issue":"12","key":"pone.0284358.ref012","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/BF03261999","article-title":"Individual NSAIDs and upper gastrointestinal complications","volume":"35","author":"J Castellsague","year":"2012","journal-title":"Drug Safety"},{"key":"pone.0284358.ref013","volume-title":"ATLAS OF OSTEOARTHRITIS","author":"N Arden","year":"2018","edition":"2"},{"key":"pone.0284358.ref014","volume-title":"Targeting outpatient drug safety: recommendations of the Dutch Harm-Wrestling Task Force","author":"MF Warl\u00e9-van Herwaarden","year":"2010"},{"key":"pone.0284358.ref015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12916-015-0285-8","article-title":"Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis\u2014an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks","volume":"13","author":"C Scarpignato","year":"2015","journal-title":"BMC Med"},{"issue":"11","key":"pone.0284358.ref016","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.joca.2019.06.011","article-title":"OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis","volume":"27","author":"RR Bannuru","year":"2019","journal-title":"Osteoarthritis Cartilage"},{"issue":"3","key":"pone.0284358.ref017","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.semarthrit.2019.04.008","article-title":"An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)","volume":"49","author":"O Bruyere","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"pone.0284358.ref018","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/apt.13642","article-title":"Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity","volume":"43","author":"JQ Yuan","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"pone.0284358.ref019","doi-asserted-by":"crossref","first-page":"11696","DOI":"10.1038\/s41598-019-48173-6","article-title":"Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users","volume":"9","author":"TJ Kim","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"pone.0284358.ref020","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/papr.12100","article-title":"Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk","volume":"14","author":"RA Moore","year":"2014","journal-title":"Pain Pract"},{"key":"pone.0284358.ref021","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.cgh.2006.08.016","article-title":"Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications","volume":"4","author":"JL Goldstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"pone.0284358.ref022","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/ajg.2012.13","article-title":"Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients","volume":"107","author":"A Lanas","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"pone.0284358.ref023","first-page":"1153","article-title":"Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use","volume":"82","author":"EN Larkai","year":"1987","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"pone.0284358.ref024","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/gut.28.5.527","article-title":"Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration","volume":"28","author":"C Armstrong","year":"1987","journal-title":"Gut"},{"issue":"10","key":"pone.0284358.ref025","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1080\/03007995.2017.1338178","article-title":"Non-steroidal anti-inflammatory drug related upper gastrointestinal bleeding: types of drug use and patient profiles in real clinical practice","volume":"33","author":"C Sostres","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"pone.0284358.ref026","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1741-7015-9-38","article-title":"Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis","volume":"9","author":"A Lanas","year":"2011","journal-title":"BMC Med"},{"key":"pone.0284358.ref027","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/ajg.2014.82","article-title":"Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis","volume":"109","author":"R Anglin","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"pone.0284358.ref028","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cger.2020.08.004","article-title":"Nonsteroidal antiinflammatory drugs, anticoagulation, and upper gastrointestinal bleeding","volume":"37","author":"M Winghin Lee","year":"2021","journal-title":"Clin Geriatr Med"},{"issue":"3","key":"pone.0284358.ref029","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2036.2010.04378.x","article-title":"Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone","volume":"32","author":"JL Goldstein","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0284358.ref030","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0016-5085(88)90482-9","article-title":"Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum","volume":"95","author":"FL Lanza","year":"1988","journal-title":"Gastroenterology"},{"key":"pone.0284358.ref031","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0895-4356(00)00365-6","article-title":"SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health","volume":"54","author":"L Rabeneck","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"pone.0284358.ref032","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1572-0241.2002.05419.x","article-title":"Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy","volume":"97","author":"L Rabeneck","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"pone.0284358.ref033","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1046\/j.1365-2125.2002.01636.x","article-title":"Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data","volume":"54","author":"SC Lewis","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0284358.ref034","unstructured":"NICE\u2014Osteoarthritis in over 16s: diagnosis and management, NICE guidance [NG226]. Published: 19 October 2022."},{"issue":"1","key":"pone.0284358.ref035","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/rheumatology\/keaa244","article-title":"Initial analgesic prescriptions for osteoarthritis in the United Kingdom, 2000\u20132016","volume":"60","author":"C Zeng","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"pone.0284358.ref036","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2340\/16501977-2119","article-title":"Gastrointestinal risk assessment in patients requiring non-steroidal anti-inflammatory drugs for osteoarthritis: The GIRANO study","volume":"48","author":"G Vanderstraeten","year":"2016","journal-title":"J Rehabil Med"},{"issue":"Suppl 3","key":"pone.0284358.ref037","first-page":"iii23","article-title":"Underutilization of preventive strategies in patients receiving NSAIDs","volume":"42","author":"MCJM Sturkenboom","year":"2003","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"pone.0284358.ref038","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/bcp.12626","article-title":"Time-trends in the prescribing of gastroprotective agents to primary care patients initiating low-dose aspirin or non-steroidal anti-inflammatory drugs: a population-based cohort study","volume":"80","author":"MF Warl\u00e9-van Herwaarden","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"pone.0284358.ref039","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/00365521.2020.1853220","article-title":"Proton pump inhibitor use among patients at risk of peptic ulcer bleeding: a nationwide register-based study","volume":"56","author":"P Fentz Haastrup","year":"2021","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"pone.0284358.ref040","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1185\/03007995.2011.580340","article-title":"Fixed-dose combination of enteric-coated naproxen and immediate-release esomeprazole has comparable efficacy to celecoxib for knee osteoarthritis: two randomized trials","volume":"27","author":"MC Hochberg","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"pone.0284358.ref041","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/00913847.2015.1074852","article-title":"Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen\/esomeprazole combination and celecoxib","volume":"43","author":"RJ Holt","year":"2015","journal-title":"Phys Sportsmed"},{"issue":"8","key":"pone.0284358.ref042","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3109\/07853890.2011.625971","article-title":"A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials","volume":"43","author":"BL Cryer","year":"2011","journal-title":"Ann Med"},{"key":"pone.0284358.ref043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/DHPS.S7329","article-title":"Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease","volume":"3","author":"DN Roberts","year":"2011","journal-title":"Drug Health Patient Saf"},{"key":"pone.0284358.ref044","first-page":"1","article-title":"Efficacy and tolerability of naproxen\/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses","volume":"5","author":"C Datto","year":"2013","journal-title":"Open Access Rheumatol"},{"issue":"1","key":"pone.0284358.ref045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11239-013-1035-4","article-title":"Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies","volume":"38","author":"DJ Angiolillo","year":"2014","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"pone.0284358.ref046","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1185\/03007995.2011.555756","article-title":"Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers","volume":"27","author":"MB Sostek","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"pone.0284358.ref047","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.cgh.2009.06.006","article-title":"Endoscopic ulcers are neither meaningful nor validated as a surrogate for clinically significant upper gastrointestinal harm","volume":"7","author":"DY Graham","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"pone.0284358.ref048","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.cgh.2009.03.032","article-title":"Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm","volume":"7","author":"A Moore","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"S3","key":"pone.0284358.ref049","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar4176","article-title":"Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage","volume":"15","author":"RA Moore","year":"2013","journal-title":"Arthritis Research & Therapy"},{"issue":"10","key":"pone.0284358.ref050","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1080\/00365521.2020.1819405","article-title":"Gastrointestinal bleeding due to peptic ulcers and erosions\u2014a prospective observational study (BLUE study)","volume":"55","author":"KK Romstad","year":"2020","journal-title":"Scand J Gastroenterol"},{"issue":"8-S","key":"pone.0284358.ref051","first-page":"72","article-title":"Helicobacter pylori, transmission routes and recurrence of infection: state of the art","volume":"89","author":"S Kayali","year":"2018","journal-title":"Acta Biomed"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0284358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T13:30:51Z","timestamp":1681392651000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0284358"}},"subtitle":[],"editor":[{"given":"Alejandro","family":"Piscoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0284358","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]}}}